Xintela AB (publ) (STO:XINT)

Market Cap	234.26M -0.5%
Revenue (ttm)	2.96M -7.7%
Net Income	-42.28M
EPS	-0.07
Shares Out	861.27M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	568,777
Average Volume	313,061
Open	0.3240
Previous Close	0.2820
Day's Range	0.2720 - 0.3240
52-Week Range	0.2380 - 0.7000
Beta	2.36
RSI	58.04
Earnings Date	Feb 27, 2026

About Xintela AB

Xintela AB (publ), a biopharma company, develops medical products in the field of stem cell therapy and targeted cancer therapy. The company’s stem cell products include XSTEM, which is in Phase I/IIa clinical development for the treatment of knee osteoarthritis, as well as in clinical study for the treatment of difficult-to-heal leg ulcers, acute respiratory distress syndrome, and other indications; and EQSTEM that is in preclinical development for the treatment of joint disease in horses. It is also developing antibody-based cancer therapies,...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2009
• Employees: 13
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: XINT

Financial Performance

In 2024, Xintela AB's revenue was 4.22 million, an increase of 5303.85% compared to the previous year's 78,000. Losses were -39.19 million, -27.54% less than in 2023.